EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR
EBR:ARGX (5/23/2025, 7:00:00 PM)
514.6
-1.8 (-0.35%)
The current stock price of ARGX.BR is 514.6 EUR. In the past month the price decreased by -3.2%. In the past year, price increased by 52.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 17.75 | 285.16B | ||
AMG.DE | AMGEN INC | 13.04 | 128.74B | ||
GIS.DE | GILEAD SCIENCES INC | 13.71 | 116.78B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.52 | 115.15B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 98.47B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.65B | ||
IDP.DE | BIOGEN INC | 7.87 | 16.14B | ||
1BIIB.MI | BIOGEN INC | 7.52 | 16.03B | ||
1MRNA.MI | MODERNA INC | N/A | 8.79B | ||
0QF.DE | MODERNA INC | N/A | 8.78B | ||
BIO.DE | BIOTEST AG | 66.15 | 1.70B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.68B |
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,599 full-time employees. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
ARGENX SE
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND NL
Employees: 1599
Phone: 31763030
The current stock price of ARGX.BR is 514.6 EUR. The price decreased by -0.35% in the last trading session.
The exchange symbol of ARGENX SE is ARGX and it is listed on the Euronext Brussels exchange.
ARGX.BR stock is listed on the Euronext Brussels exchange.
26 analysts have analysed ARGX.BR and the average price target is 699 EUR. This implies a price increase of 35.83% is expected in the next year compared to the current price of 514.6. Check the ARGENX SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARGENX SE (ARGX.BR) has a market capitalization of 31.42B EUR. This makes ARGX.BR a Large Cap stock.
ARGENX SE (ARGX.BR) currently has 1599 employees.
ARGENX SE (ARGX.BR) has a support level at 502.83 and a resistance level at 562.77. Check the full technical report for a detailed analysis of ARGX.BR support and resistance levels.
The Revenue of ARGENX SE (ARGX.BR) is expected to grow by 64.81% in the next year. Check the estimates tab for more information on the ARGX.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARGX.BR does not pay a dividend.
ARGENX SE (ARGX.BR) will report earnings on 2025-07-31, before the market open.
The PE ratio for ARGENX SE (ARGX.BR) is 108.79. This is based on the reported non-GAAP earnings per share of 4.73 and the current share price of 514.6 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.BR.
ChartMill assigns a technical rating of 3 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 90.05% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ARGX.BR. While ARGX.BR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 4.73. The EPS increased by 194.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 37.99% | ||
ROA | 13.41% | ||
ROE | 15.13% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 85% to ARGX.BR. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of 576.65% and a revenue growth 64.81% for ARGX.BR